Dexcom (DXCM) Liabilities and Shareholders Equity (2010 - 2026)

Dexcom (DXCM) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $6.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 11.9% year-over-year to $6.5 billion in Q2 2026; TTM through Jun 2026 was $26.9 billion, a 0.04% change from a year earlier, with the FY2025 full-year figure at $6.3 billion, down 2.23% from the prior year.
• Liabilities and Shareholders Equity was $6.5 billion for Q2 2026 at Dexcom, down from $6.6 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $7.5 billion in Q3 2025 and troughed at $4.9 billion in Q3 2022.
• A 5-year average of $6.3 billion and a median of $6.5 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 34.64% in 2023 and decreased 11.9% in 2026, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $5.4 billion in 2022, then grew by 16.19% to $6.3 billion in 2023, then grew by 3.51% to $6.5 billion in 2024, then decreased by 2.23% to $6.3 billion in 2025, then grew by 1.82% to $6.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $6.5 billion (Q2 2026), $6.6 billion (Q1 2026), and $6.3 billion (Q4 2025), per Business Quant data.